October 13, 2023 11:06 AM EDT

Harmony Biosciences' Wakix fails PhIII hypersomnia study; Florida gene therapy startup downsizes

Kyle LaHucik

Senior Reporter

Amber Tong

Plus Phase II data on ABION’s MET tyrosine kinase inhibitor, and 60 Degrees Pharmaceuticals giving up on repurposing its antimalarial drug for Covid-19.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Harmony Biosciences' Wakix fails PhIII hypersomnia study; Florida gene therapy startup downsizes

Kyle LaHucik

Senior Reporter

Amber Tong

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Merck’s long-awaited obesity move is an oral GLP-1 from China

Major PBM reforms feature in Congress' year-end spending bill

What Trump’s FTC picks mean for biopharma dealmaking and PBMs

Updated: Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

Har­mo­ny Bio­sciences' Wak­ix fails PhI­II hy­per­som­nia study; Flori­da gene ther­a­py start­up down­sizes

Senior Reporter

Sign up to read this article for free.

more like this

Harmony Biosciences' Wakix fails PhIII hypersomnia study; Florida gene therapy startup downsizes